GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase I)
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2016
At a glance
- Drugs Antithrombotics (Primary)
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- Acronyms GLORIA-AF
- Sponsors Boehringer Ingelheim
- 04 Dec 2016 The results were presented at the American Society of Hematology (ASH) Annual Meeting, as reported by Boehringer Ingelheim media release.
- 04 Dec 2016 Results published in the Boehringer Ingelheim Media Release
- 09 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.